


Veracyte, Inc. (VCYT)

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001384101

[illegible]

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

-Driving Global Growth with Distributed IVD Tests. Currently, the Prosigna Breast Cancer Assay is available globally as an IVD test that runs on the nCounter Analysis System platform. If we are not able to adapt our other current or future tests to be performed on IVD platforms or if our tests fail to be competitive against competing products in international markets, our prospects for growth could suffer. In addition, to the extent international markets have existing practices and standards of care that are different than those

in the United States, we may face challenges with the adoption of our tests in international markets.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 58.2						
Gross profitability		25.8%	32.2%	55.5	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(5.2%)	(6.6%)	60.9	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 12.9						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		15.66	(0.31)	4.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31
Current ratio		8.15x	2.96x	21.5	839	2025-12-31
Growth and financing, sleeve percentile 28.6						
Revenue growth, three-year compound		20.4%	10.0%	30.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		218.9%	37.1%	14.6	104	2025-12-31
Asset growth, three years		6.7%	2.1%	37.3	704	2025-12-31
Net share issuance, one year		1.9%	2.5%	32.1	634	2026-02-20

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
27	Intuitive Surgical Inc. (ISRG)	7.0	A	
28	iRhythm Holdings, Inc. (IRTC)	7.3	A	fortress
				balance sheet
29	Globus Medical Inc. (GMED)	7.6	A	
30	Hims & Hers Health, Inc. (HIMS)	7.8	A	
31	Gyre Therapeutics, Inc. (GYRE)	8.1	A	fortress
				balance sheet
32	Veracyte, Inc. (VCYT) <	8.4	A	
33	Alkermes plc. (ALKS)	8.6	A	
34	Si-Bone, Inc. (SIBN)	8.9	A	fortress
				balance sheet
35	Viridian Therapeutics, Inc.\DE (VRDN)	9.2	A	dilution,
				fortress
				balance sheet
36	Xtant Medical Holdings, Inc. (XTNT)	9.5	A	fortress
				balance sheet
37	Viemed Healthcare, Inc. (VMD)	9.7	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	25.8%	8.0%	62
Distance from 52-week high	(27.9%)	(31.4%)	55
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	3.6%	(1.0%)	72
Book value to price	0.40	0.28	61
Sales to price	0.15	0.31	34
Composite equity issuance, five years	18.2%	20.3%	48
Relative strength against the sector, log excess return	0.02	(0.14)	62

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	

Cash and equivalents	\$299.5M
Operating cash flow, four quarters	\$178.4M
Months of runway	not finite
Days since last periodic filing	70 (10-Q received Jul 31, 2026)
Median daily dollar volume, 63 sessions	\$55.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$362.5M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
2	assets	us-gaap:Assets	\$1.4B	2025-12-31	2026-02-26	10-K	0001384101-26-000010
3	net income	us-gaap:NetIncomeLoss	\$66.4M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$136.3M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
5	assets	us-gaap:Assets	\$1.3B	2024-12-31	2026-02-26	10-K	0001384101-26-000010
6	current assets	us-gaap:AssetsCurrent	\$488.4M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
7	current liabilities	us-gaap:LiabilitiesCurrent	\$59.9M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$377.6M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
9	operating income	us-gaap:OperatingIncomeLoss	\$57.8M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
10	book equity	us-gaap:StockholdersEquity	\$1.3B	2025-12-31	2026-02-26	10-K	0001384101-26-000010
11	liabilities	us-gaap:Liabilities	\$96.4M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
12	operating income	us-gaap:OperatingIncomeLoss	-\$35.4M	2020-12-31	2023-03-01	10-K	0001384101-23-000016
13	interest expense	us-gaap:InterestExpense	\$229,000	2020-12-31	2021-02-22	10-K	0001384101-21-000012
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$517.1M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$445.8M	2024-12-31	2026-02-26	10-K	0001384101-26-000010
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$361.1M	2023-12-31	2026-02-26	10-K	0001384101-26-000010
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$296.5M	2022-12-31	2025-02-28	10-K	0001384101-25-000014
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$9.7M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$75.1M	2024-12-31	2026-02-26	10-K	0001384101-26-000010
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$11.3M	2024-12-31	2026-02-26	10-K	0001384101-26-000010
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$44.2M	2023-12-31	2026-02-26	10-K	0001384101-26-000010
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$10.0M	2023-12-31	2026-02-26	10-K	0001384101-26-000010
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$7.5M	2022-12-31	2025-02-28	10-K	0001384101-25-000014
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.5M	2022-12-31	2025-02-28	10-K	0001384101-25-000014
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$21.4M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$58.2M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
27	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.8M	2025-12-31	2026-02-26	10-K	0001384101-26-000010
28	current assets	us-gaap:AssetsCurrent	\$372.3M	2024-12-31	2026-02-26	10-K	0001384101-26-000010
29	current liabilities	us-gaap:LiabilitiesCurrent	\$78.6M	2024-12-31	2026-02-26	10-K	0001384101-26-000010
30	assets	us-gaap:Assets	\$1.1B	2023-12-31	2025-02-28	10-K	0001384101-25-000014
31	assets	us-gaap:Assets	\$1.2B	2022-12-31	2024-02-29	10-K	0001384101-24-000017
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	79,458,427	2026-02-20	2026-02-26	10-K	0001384101-26-000010
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	77,944,772	2025-02-21	2025-02-28	10-K	0001384101-25-000014